Targeting mTOR dependency in pancreatic cancer. [electronic resource]
Producer: 20140930Description: 1481-9 p. digitalISSN:- 1468-3288
- Animals
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- antagonists & inhibitors
- Carcinoma, Pancreatic Ductal -- diagnostic imaging
- Cell Line, Tumor
- Drug Administration Schedule
- Gene Expression Regulation, Neoplastic
- Humans
- Injections, Intraperitoneal
- Mice
- Mice, Mutant Strains
- Mutation
- PTEN Phosphohydrolase -- deficiency
- Pancreatic Neoplasms -- diagnostic imaging
- Positron-Emission Tomography
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins p21(ras) -- deficiency
- Sirolimus -- therapeutic use
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Treatment Outcome
- Tumor Suppressor Protein p53 -- deficiency
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.